Post by Bram De Laere

📣 Our commentary on the ProBio-mHSPC platform trial has been published on UroToday + GU OncToday! 🎉 🌐 Beyond the Abstract link: https://lnkd.in/emMinz49 💡 We discuss how 🩸ctDNA 🧬 may transform treatment selection for men with metastatic hormone-sensitive #ProstateCancer through a biomarker-driven clinical trial design. The ProBio-mHSPC platform aims to: ✅ Personalize treatment based on molecular #Biomarkers ✅ Adapt therapy through ctDNA-guided de-escalation and intensification ✅ Accelerate the evaluation of #PrecisionOncology strategies ✅ Improve outcomes while minimizing unnecessary treatment 🙏 A big thank you to all collaborators who contribute to this initiative! Johnson & Johnson Bayer Kom op tegen Kanker Cancerfonden Vetenskapsrådet / Swedish Research Council Swiss Cancer Foundation Giuliana and Giorgio Stefanini Foundation, and Swiss Cancer League beider Basel 💬 Share your thoughts on biomarker-driven platform trials and the future of ctDNA-guided treatment in prostate cancer. #LiquidBiopsy #ctDNA #ClinicalTrials #PrecisionMedicine #Oncology #Urology #TranslationalResearch #CancerResearch #mHSPC #ProBio #UroToday